Compare ASTH & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | ENOV |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Fluid Controls |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | ASTH | ENOV |
|---|---|---|
| Price | $26.95 | $24.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $41.33 | ★ $48.13 |
| AVG Volume (30 Days) | 514.0K | ★ 982.8K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,896,452,000.00 | $2,233,266,000.00 |
| Revenue This Year | $58.46 | $9.22 |
| Revenue Next Year | $25.59 | $4.60 |
| P/E Ratio | $140.25 | ★ N/A |
| Revenue Growth | ★ 68.17 | 11.57 |
| 52 Week Low | $20.12 | $23.58 |
| 52 Week High | $39.97 | $49.38 |
| Indicator | ASTH | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 35.40 |
| Support Level | $25.52 | $23.58 |
| Resistance Level | $27.80 | $24.94 |
| Average True Range (ATR) | 1.34 | 1.33 |
| MACD | 0.03 | -0.32 |
| Stochastic Oscillator | 52.06 | 7.29 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.